Virax Biolabs Group Limited (VRAX)
VRAXNASDAQ-CMBiotechnology: In Vitro & In Vivo Diagnostic Substances
$0.6000
-0.1099 (-15.48%) today
Regular session, Nov 10, 3:27 PM ET
- Market cap
- $807.0k
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- $0.5200 to $0.7000
- 52-week range
- $0.6300 to $21.75
- Average volume
- 412.0k
- Previous close
- $0.7099
Earnings
Next report
Financials
| Quarter | Mar 2020 |
|---|---|
| Revenue | $100.0k |
| Gross profit | $46.0k |
| Operating income | -$651.0k |
| Net income | -$710.0k |
News
8 latest- Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch RTTNews · Jul 16, 2026
- Weekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal RTTNews · Jul 10, 2026
- Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch RTTNews · Jul 9, 2026
- Virax Signs Multi-Country Commercial Supply Agreement With Fosun Diagnostics; Stock Skyrockets RTTNews · Jul 9, 2026
- Virax CEO Foster Releases Shareholder Letter Regarding Upcoming Milestones RTTNews · Apr 14, 2026
- Stocks To Watch Today: IDYA, OGN, VRX, REPL... RTTNews · Apr 13, 2026
- Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's WhyZacks · Jan 15, 2026
- Virax Biolabs Unveils $5 Million Private Placement RTTNews · Dec 4, 2025
The company
Virax Biolabs Group Limited is a biotechnology company focused on immune response detection and T cell immune profiling. The Company is developing in vitro diagnostic technologies for viral and immune-mediated diseases, with an initial strategic focus on post-acute infection syndromes, including Long COVID, and related areas of chronic immune dysfunction. Its principal programs are ViraxImmune, an in-development T cell-based immune profiling and diagnostic platform, and ImmuneSelect, a research-use-only portfolio of peptide pools, ELISpot plates and related immune reagents.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ-CM
- Region
- Europe
- Website
- viraxbiolabs.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.